66529-17-7

66529-17-7 structure

Name: Midaglizole
Chemical Name: Midaglizole
CAS Number: 66529-17-7
Molecular Formula: C₁₆H₁₇N₃
Molecular Weight: 251.32600
Catalog: Signaling Pathways GPCR/G Protein Adrenergic Receptor
Create Date: 2018-09-17 17:48:09
Modify Date: 2024-01-02 18:29:14
Midaglizole ((±)-DG5128 free base, DG5128 free base) is a potent α2-adrenoceptor antagonist. Midaglizole is a hypoglycemic agent. Midaglizole increases blood pressure and reduces blood glucose levels in vivo[1][2][3].

Name	Midaglizole
Synonyms	2-[2-(2-Imidazolin-2-yl)-1-phenylethyl]pyridine 2-[2-Phenyl-2-(pyridyl)]ethyl-2-imidazolin 2-(4,5-dihydro-1H-imidazol-2-yl)-1-phenyl-1-[2]pyridyl-ethane 4,5-Dihydro-2-[2-(2-pyridinyl)-2-phenylethyl]-1H-imidazole DG-5128 2-(4,5-Dihydro-1H-imidazol-2-yl)-1-phenyl-1-[2]pyridyl-aethan 2-(2-phenyl-2-(2-pyridyl))ethyl-2-imidazoline

Description	Midaglizole ((±)-DG5128 free base, DG5128 free base) is a potent α2-adrenoceptor antagonist. Midaglizole is a hypoglycemic agent. Midaglizole increases blood pressure and reduces blood glucose levels in vivo[1][2][3].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor Research Areas >> Metabolic Disease
In Vitro	Midaglizole stimulates insulin release with the EC50 values of 200 nM, 24 µM for rat islets and MIN6 β-cell line, respectively[3].
In Vivo	Midaglizole (3, 30 mg/kg; i.v.) increases blood pressure in rats[1]. Midaglizole (0.2, 1, 2 mg/kg; infusion) reduces blood glucose levels in dags[2]. Animal Model: 290-450 g, Male Wistar rats[1] Dosage: 3, 30 mg/kg Administration: I.v. Result: Increased the blood pressure by 27 and 64 mmHg at 3, 30 mg/kg, respectively. Animal Model: Dogs[2] Dosage: 0.2, 1, 2 mg/kg Administration: Superior pancreaticoduodeneal artery infusion Result: Reduced blood glucose levels by stimulating insulin release from the pancreatic islets.
References	[1]. Hirohashi M, et al. Intrinsic pressor activity of midaglizole, an alpha-2 adrenoceptor antagonist, in pithed rats. Jpn J Pharmacol. 1990 Aug;53(4):519-20. [2]. Ohneda K, et al. Mechanism of insulin secretion by midaglizole. Diabetes Res Clin Pract. 1993 Feb;19(2):127-32. [3]. Proks P, et al. Inhibition of recombinant K(ATP) channels by the antidiabetic agents midaglizole, LY397364 and LY389382. Eur J Pharmacol. 2002 Sep 27;452(1):11-9.

HS Code	2933990090

72157-11-0

~97%

66529-17-7

Literature: Ishikawa Chemical and pharmaceutical bulletin, 1980 , vol. 28, # 5 p. 1394 - 1402

91-02-1

66529-17-7

Literature: Ishikawa Chemical and pharmaceutical bulletin, 1980 , vol. 28, # 5 p. 1394 - 1402

76132-37-1

66529-17-7

Literature: Ishikawa Chemical and pharmaceutical bulletin, 1980 , vol. 28, # 5 p. 1394 - 1402

14034-59-4

76132-65-5

~67%

66529-17-7

Literature: Ishikawa Chemical and pharmaceutical bulletin, 1980 , vol. 28, # 5 p. 1394 - 1402

76132-63-3

107-15-3

66529-17-7

76132-49-5

66529-17-7

Literature: Ishikawa Chemical and pharmaceutical bulletin, 1980 , vol. 28, # 5 p. 1394 - 1402

101-82-6

50342-08-0

66529-17-7

Literature: Schering Corp. Patent: US2604473 , 1950 ;

HS Code	2933990090
Summary	2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%